doxorubicin hydrochloride has been researched along with Breast Cancer in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (83.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Agrawal, SK; Rani, R; Roy, P; Saxena, AK; Singh, J; Sondhi, SM | 1 |
| Bharathi, EV; Dastagiri, D; Kamal, A; Pal-Bhadra, M; Pushpavalli, SN; Ramaiah, MJ; Reddy, JS; Reddy, MK; Sarma, P; Srikanth, YV | 1 |
| Archana, S; Das, A; Dixit, A; Geesala, R; Panasa, A; Puroshottam, G; Rao, NB; Satpati, S; Srivastava, AK | 1 |
| Bist, G; Jun, KY; Kadayat, TM; Kwon, Y; Lee, ES; Magar, TB; Na, Y; Park, S; Shrestha, A | 1 |
| Makhafola, TJ; Mmonwa, MM; Mphahlele, MJ | 1 |
| Islam, MS; Kadi, AA; Kwon, Y; Park, S; Rahman, AF; Song, C | 1 |
| Bandgar, BP; Bhale, PS; Chavan, HV; Dongare, SB; Mule, YB; Nagane, SS; Shringare, SN | 1 |
| Barkume, M; Chandra Shekar, K; Jadhav, S; Juvekar, A; Kamal, A; Khan, I; Kode, J; Kumar, CG; Kumar, GB; Pal-Bhadra, M; Patel, N; Rao, GK; Reddy, VS; Routhu, SR; Shaik, AB; Veena, I | 1 |
| Ai, W; Bao, N; Chen, H; Li, S; Li, W; Wang, S | 1 |
| Hwang, SY; Jeon, YH; Jeong, TC; Jo, H; Kadayat, TM; Katila, P; Kim, KS; Kim, SK; Koh, WS; Kwon, Y; Lee, ES; Nepal, MR; Noh, K; Park, S; Shrestha, A; Shrestha, R | 1 |
| Gong, S; Hong, K; Liang, JJ; Liu, TY; Qin, KM; Xie, BH; Yan, JJ; Yang, L; Yin, YP; Yu, WL; Zhou, HB | 1 |
| Chen, L; Sun, J; Wu, C; Zhang, J; Zhao, M; Zhong, H | 1 |
12 other study(ies) available for doxorubicin hydrochloride and Breast Cancer
| Article | Year |
|---|---|
Solvent free synthesis, anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Microwaves; Neoplasms; Ovarian Neoplasms | 2010 |
Synthesis and biological evaluation of estradiol linked pyrrolo[2,1-c][1,4]benzodiazepine (PBD) conjugates as potential anticancer agents.
Topics: Antineoplastic Agents; Benzodiazepines; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Estradiol; Estrogens; Female; Humans; Pyrroles; Structure-Activity Relationship; Tubulin | 2011 |
Development of constrained tamoxifen mimics and their antiproliferative properties against breast cancer cells.
Topics: Binding Sites; Boronic Acids; Breast Neoplasms; Catalysis; Cell Line, Tumor; Cell Proliferation; Coordination Complexes; Estrogen Receptor alpha; Female; Humans; MCF-7 Cells; Molecular Docking Simulation; Palladium; Protein Structure, Tertiary; Tamoxifen | 2015 |
Effect of chlorine substituent on cytotoxic activities: Design and synthesis of systematically modified 2,4-diphenyl-5H-indeno[1,2-b]pyridines.
Topics: Antineoplastic Agents; Biphenyl Compounds; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Design; Female; Halogenation; HeLa Cells; Humans; Indenes; Pyridines; Structure-Activity Relationship; Topoisomerase Inhibitors | 2016 |
In vitro cytotoxicity of novel 2,5,7-tricarbo-substituted indoles derived from 2-amino-5-bromo-3-iodoacetophenone.
Topics: Acetophenones; Amination; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Female; Halogenation; HeLa Cells; Humans; Indoles; MCF-7 Cells; Uterine Cervical Neoplasms | 2016 |
Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIα catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells.
Topics: Animals; Antigens, Neoplasm; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; Fluorescein; G1 Phase Cell Cycle Checkpoints; Humans; Hydrazones; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2017 |
Synthesis of extended conjugated indolyl chalcones as potent anti-breast cancer, anti-inflammatory and antioxidant agents.
Topics: Albumins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Chalcones; Chlorocebus aethiops; Diclofenac; Doxorubicin; Egg Proteins; Female; Free Radical Scavengers; Humans; Indoles; MCF-7 Cells; Nitric Oxide; Protein Denaturation; Structure-Activity Relationship; Superoxides; Vero Cells | 2017 |
Design, synthesis and biological evaluation of novel pyrazolochalcones as potential modulators of PI3K/Akt/mTOR pathway and inducers of apoptosis in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Chalcones; Dose-Response Relationship, Drug; Drug Design; Female; Humans; MCF-7 Cells; Molecular Structure; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Structure-Activity Relationship; TOR Serine-Threonine Kinases | 2017 |
The inhibitory effect of kokusaginine on the growth of human breast cancer cells and MDR-resistant cells is mediated by the inhibition of tubulin assembly.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dictamnus; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Furans; Humans; MCF-7 Cells; Molecular Structure; Quinolines; Structure-Activity Relationship; Tubulin | 2018 |
Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Breast Neoplasms; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Humans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred ICR; Microwaves; Molecular Structure; Pyridines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2019 |
Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents; Apoptosis; Biological Products; Breast Neoplasms; Cell Proliferation; Down-Regulation; Estrogen Receptor alpha; Humans; Letrozole; MCF-7 Cells; Molecular Docking Simulation; Protein Binding; Proteolysis; Raloxifene Hydrochloride; Reactive Oxygen Species; Sesterterpenes; Signal Transduction; Structure-Activity Relationship; Tamoxifen | 2022 |
Development of oxoisoaporphine derivatives with topoisomerase I inhibition and reversal of multidrug resistance in breast cancer MCF-7/ADR cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; DNA Topoisomerases, Type I; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Molecular Docking Simulation | 2022 |